Business Monitor International

Pharmaceuticals & Healthcare Reports

Argentina Pharmaceuticals & Healthcare Report

Published: 18 Aug 2011 Quarterly

Report Downloads

Independent pharmaceutical and healthcare industry forecasts to end-2016 for Argentina.
Original pharmaceutical and healthcare market research and sector trend analysis for the Argentinian pharmaceutical and healthcare industry.
Competitor intelligence, Company Profiles and Competitive Landscape Tables on pharmaceutical and healthcare companies in Argentina.

Includes 3 FREE quarterly updates

Price: $995.00

You save $180.00 (15%) on the regular rate

Order and Enquiries

Related Products

Argentina Products

Argentina Business Forecast Report

The Argentina Business Forecast Report provides essential macroeconomic, political and financial analysis for companies doing business in Argentina. Read More

Multinational Companies in Argentina CD-ROM

The Multinational Companies in Argentina CD-ROM 2011 database features 2930 fully researched, senior executive contacts and top decision makers at 870 multinational companies in Argentina. Read More

Pharmaceuticals & Healthcare Products

Brazil Pharmaceuticals & Healthcare Report

The Brazil Pharmaceuticals & Healthcare Report has been researched at source and features the latest available data and forecasts to end-2012, covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade. Read More

Central America Pharmaceuticals & Healthcare Report

When taken as a whole, the pharmaceutical market of Central America is an attractive prospect for drugmakers. Combined sales of prescription drugs and over-the-counter (OTC) medicines are forecast to increase from US$2.35bn in 2009 to US$2.49bn in 2010. This equates to respectable 6.1% growth and makes Central America’s pharmaceutical market the sixth-largest in Latin America, behind Puerto Rico (US$2.71bn) and ahead of Colombia (US$2.24bn). Read More

Report Description

The Argentina Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts to end-2016 for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Argentina Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Argentinian pharmaceutical and healthcare industry.

Key Benefits

Benchmark BMI's independent pharmaceutical and healthcare industry forecasts to end-2016 on Argentina to test other views - a key input for successful budgeting and strategic business planning in the Argentinian pharmaceutical and healthcare market.
Target business opportunities and risks in the Argentinian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Argentina.
Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

Download Table of Contents

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation, advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecast To End-2016

Forecasts to end-2016 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.